Company profile: Amphivena Therapeutics
1.1 - Company Overview
Company description
- Provider of a platform of dual-function biologics in clinical-stage immuno-oncology.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Amphivena Therapeutics
Compass Therapeutics
HQ: United States
Website
- Description: Provider of immune system–targeting therapeutics and antibody engineering platforms. Pipeline: CTX-009, a DLL4/VEGF-A bispecific showing benefit in colorectal and gastric cancers; CTX-471, a CD137 agonist for melanoma with U.S. studies planned H2 2024; and CTX-8371, a PD-1/PD-L1 bispecific in preclinical development for solid tumors. Platforms: StitchMabs for bispecifics, common light chain discovery, and human display for antibody tuning.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Compass Therapeutics company profile →
Siren Biotechnology
HQ: United States
Website
- Description: Provider of AAV immuno-gene therapies that combine AAV gene therapy and cytokine immunotherapy into a single modality for solid tumors, including brain and eye cancers. Its approach delivers engineered cytokines directly to tumors to activate immune responses and destroy cancer cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Siren Biotechnology company profile →
Tilt Biotherapeutics
HQ: Finland
Website
- Description: Provider of oncolytic viral cancer immunotherapies that enable tumor T-cell therapy by modifying the tumor microenvironment. Pipeline includes TILT-123 (cytokine-armed oncolytic adenovirus, in Phase 1), TILT-234 (Ad3 armed with human CD40L, ready for CMC/regulatory), TILT-321/322 (bispecific antibody-coding adenoviruses, discovery), and TILT-452 (preclinical), with clinical trial collaborations on TILT-123 with Merck KGaA and MSD.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tilt Biotherapeutics company profile →
Neogene Therapeutics
HQ: The Netherlands
Website
- Description: Provider of T cell therapies targeting cancer neo-antigens, developing technologies to engineer designer T cells with optimized neo-antigen specificities to seek and destroy cancer cells. Offers engineered TCR therapies for solid tumors, including a TP53 R175H-targeting TCR therapy currently in Phase I trials in the US.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neogene Therapeutics company profile →
Kymera Therapeutics
HQ: United States
Website
- Description: Provider of targeted protein degradation therapeutics, leveraging TPD to eliminate disease-causing proteins, developing investigational degraders KT-474 (IRAK4) in Phase 2 for hidradenitis suppurativa and atopic dermatitis; KT-333 (STAT3) in Phase 1 for hematological malignancies and solid tumors; and KT-253 (MDM2) in Phase 1 for high-grade myeloid malignancies, lymphomas, and solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kymera Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Amphivena Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Amphivena Therapeutics
2.2 - Growth funds investing in similar companies to Amphivena Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Amphivena Therapeutics
4.2 - Public trading comparable groups for Amphivena Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →